Progress and Controversies in Gynecologic Oncology - priME Oncology
prIME Downloadable Slides
prIME Downloadable Slides

Progress and Controversies in Gynecologic Oncology

Downloadable Slides From a 2018 prIME Oncology Conference

Not a member of My prIME? Join now for instant access.

prIME Oncology invites you to view downloadable slides from the 2018 Progress and Controversies in Gynecologic Oncology Conference held in Barcelona, Spain.

Downloadable Slides

Downloadable Slides

IME

IME

Release Date

Release Date

Jan 25, 2018

Expiration Date

Jan 25, 2019

Session I: Endometrial Cancer

Individualized management of FIGO stage IB-II, G3 endometrial cancer: A case for surgery alone ± brachytherapy

Featured Expert: Ignace Vergote, MD, PhD

Individualized management of FIGO stage IB-II, G3 endometrial cancer:  A case for surgery + chemotherapy

Featured Expert: Mansoor R. Mirza, MD

Debate Pro: Is there any role for external radiotherapy in FIGO stage III endometrial cancer?

Featured Expert: Remi Nout, MD, PhD

Debate Contra: Is there any role for external radiotherapy in FIGO stage III endometrial cancer?

Featured Expert: David Miller, MD, FACOG, FACS

Special Session—The Role of Sentinel Node Procedures in Cervical and Endometrial Cancers

Update on sentinel node biopsy in endometrial cancer: Feasibility, technique, and impact

Featured Expert: Bjørn Hagen, MD, PhD

Update on sentinel node procedures in cervical cancer: Feasibility, technique, and impact

Featured Expert: Nadeem R. Abu-Rustum, MD, FACOG, FACS

Session II: Lower Gestational Tract and Beyond

New approaches and developments in the systemic treatment of cervical cancer

Featured Expert: Bradley J. Monk, MD, FACS, FACOG

New approaches and developments in the systemic treatment of endometrial cancer

Featured Expert: Andrés Poveda, MD

Special Session—Hot Topics in Gynecologic Oncology

Update on the management of nonepithelial ovarian cancer

Featured Expert: Christian Marth, MD, PhD

Keynote lecture—DNA damage response and resistance mechanisms to PARP inhibitors

Featured Expert: Jonathan Ledermann, BSc, MD, FRCP

Current perspectives on biomarkers for targeted therapies and immunotherapies in gynecologic malignancies

Featured Expert: Eric Pujade-Lauraine, MD, PhD

Session III: Ovarian Neoplasm I

How to select the right patient for upfront surgery or chemotherapy

Featured Expert: Andreas du Bois, MD, PhD

Is there still a role for systematic lymphadenectomy at primary debulking surgery for ovarian cancer?

Featured Expert: Philipp Harter, MD, PhD

A critical appraisal of HIPEC in ovarian cancer

Featured Expert: Luis Chiva, MD, PhD

Update on secondary surgery for recurrent ovarian cancer

Featured Expert: Stefano Greggi, MD, PhD

Session IV: Ovarian Neoplasm II

Interactive clinical case—Front-line therapy: Incorporating targeted therapies

Featured Expert: Nicoletta Colombo, MD, PhD

Interactive clinical case—Recurrent disease and platinum seems to be an option

Featured Expert: Antonio González-Martín, MD

Interactive clinical case—Recurrent disease and platinum seems not to be an option

Featured Expert: Ana Oaknin, MD, PhD

Session V: Challenging Issues in Clinical Practice

The ESGO initiative on quality of centers and education

Featured Expert: Denis Querleu, MD

Tertiary surgery: Is it really an option?

Featured Expert: Christina Fotopoulou, MD, PhD

Palliative care: Surgical and nonsurgical management of acute or subacute bowel obstruction

Featured Expert: Giovanni Aletti, MD

High-risk recurrent gestational trophoblastic disease

Featured Expert: Michael Seckl, MD, PhD, FMedSci

The 2018 Progress and Controversies in Gynecologic Oncology Conference is intended for gynecologists, oncologists, radiation therapists, surgeons, pathologists, and other practitioners including allied health professionals involved in the diagnosis and management of gynecologic malignancies.

After successful completion of this educational activity, participants should be able to:

  • Develop practical approaches for the management of cervical cancer and endometrial cancer
  • Describe optimal management of gestational trophoblastic disease
  • Assess standard and emerging therapeutic options for ovarian cancer and describe how the options impact patient outcomes

This educational activity is supported by AstraZeneca, Clovis Oncology, ImmunoGen, PharmaMar, and TESARO.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Abu-Rustum has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Aletti has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr du Bois has disclosed that he has received honoraria or consultation fees from Advaxis, AstraZeneca, Pfizer Inc., PharmaMar, Roche, and Tesaro. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Chiva has disclosed that he has received grants or research support from Medtronic, Roche, and Takeda. He has also received honoraria or consultation fees from AstraZeneca, Roche, and Takeda, and participated in sponsored speaker’s bureaus for Roche and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Colombo has disclosed that she has received honoraria or consultation fees from Advaxis, Amgen, AstraZeneca, Clovis, Merck Sharp & Dohme, Pfizer Inc., PharmaMar, Roche, and Tesaro. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Fotopoulou has disclosed consulting on advisory boards for AstraZeneca, Olympus, Pharmacokinesis, Roche, and Tesaro. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr González-Martín has disclosed that he has received honoraria or consultation fees and participated in company sponsored speaker’s bureaus from AstraZeneca, PharmaMar, Roche, and Tesaro. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Greggi has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Hagen has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Harter has disclosed that he has received grants or research support from AstraZeneca, Clovis, Lilly, PharmaMar, Roche, and Sotio, and Tesaro. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Ledermann has disclosed that he has received grants or research support from AstraZeneca. He has also consulted on advisory boards for AstraZeneca, Clovis, Pfizer, and Roche, and participated in sponsored speaker’s bureaus for AstraZeneca, Clovis, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Marth has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Miller has disclosed that he has received grants or research support from Advaxis, Aeterna Zentaris, AstraZeneca, Gyn Onc Group, Janssen, NRG Oncology, Pfizer, SCRI Development Innovations, Tesaro, Tracon, and VentriRX Pharmaceuticals. He has also received honoraria or consultation fees from Alexion, AstraZeneca, Clovis, Eisai, Gaurdent, Genentech, and Tesaro, and has participated in sponsored speaker bureaus for Clovis and Genentech. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Mirza has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Monk has disclosed that he has received honoraria or consultation fees from AbbVie, Advaxis, Amgen, AstraZeneca, Biodesix, Clovis, Genmab, Gradalis, Immunogen Inc, Incyte, Insys, Mateon Therapeutics Inc (formerly Oxigene), Merck, Myriad, Perthera, Pfizer, Precision Oncology, Roche/Genentech, and Tesaro.  He has also participated in sponsored speaker’s bureaus for AstraZeneca, Clovis, Janssen, Johnson & Johnson, Roche/Genentech, and Tesaro. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Nout has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Oaknin has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Poveda has disclosed that he has received grants or research support from Roche. He has also received honoraria or consultation fees from AstraZeneca, Clovis, PharmaMar, Roche, and Tesaro. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Pujade-Lauraine has disclosed that he has received honoraria or consultation fees from AstraZeneca, Clovis, Pfizer, Roche, and Tesaro. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Querleu has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Seckl has disclosed that he has received honoraria or consultation fees from Bristol Myer Squibb. He has also participated in sponsored speaker’s bureau for Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Vergote has disclosed consulting on advisory boards for Advaxis Inc, Amgen Inc, AstraZeneca, Bayer Pharma AG, Cerulean Pharma Inc, Debiopharma International SA, Eli Lilly Benelux NV, F. Hoffmann-La Roche Ltd, GCI Health, Genmab A/S, Immunogen Inc, Janssen-Cilag, Mateon Therapeutics Inc, Morphotek, Nektar Therapeutics, MSD Belgium BVBA, Novartis Pharma AG, Novocure GMBH, Oncoinvent AS, Oxigene Inc, Pfizer, Roche, Theradex Europe Limited, and Vifor Pharma België NV. Dr Vergote has also disclosed that he has performed contracted research via KU Leuven, that he has received grant support (corporate-sponsored research) from Amgen and Roche, and that he has received support for accommodation and travel expenses from Elsevier, Tesaro, and Theradex. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Amy Furedy, RN, OCN (clinical content reviewer/planner) – no relevant financial relationships
  • Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.